Abacavir is a nucleoside reverse transcriptase inhibitor used for combination antiretroviral therapy for treating human immunodeficiency virus (HIV) infection. An adverse effect from abacavir is a treatment-limiting hypersensitivity reaction, which can be severe and potentially life-threatening. Abacavir-induced hypersensitivity reaction has been associated with the presence of the major histocompatibility complex class I allele HLA-B*5701. A screening test for the HLA-B*5701 allele can assist clinicians to identify patients who are at risk of developing a hypersensitivity reaction to abacavir.
Test Description
Sequence-based genotyping and polymerase chain reaction (PCR) sequencing of specific oligonucleotide probes are the most widely used techniques. To test for the HLA-B*5701 allele, a blood or saliva specimen is collected. The genetic sequences coding for the HLA-B*5701 are probed and reported as positive if the allele is present, or negative if the allele is absent.
Guidelines by professional groups
The Infectious Diseases Society of America (IDSA) has issued clinical guidelines which state "HLA-B*5701 testing should be performed prior to initiating abacavir therapy to reduce the risk of a hypersensitivity reaction. Patients who are positive for the HLA-B*5701 haplotype should not be treated with abacavir" [14] .
Other groups
In July 2008, the U.S. Food and Drug Administration (FDA) issued a post-marketing communication [15] to update the prescribing information for abacavir. The updated black box warning stated "Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction" [16] .
Evidence Overview
Analytic Validity : Test accuracy and reliability in measuringthe HLA-B*5701 allele (analytic sensitivity and specificity).
Among 4 international laboratories, analytic specificity of detecting the HLA-B*5701 allele via PCR sequencing was 100% [17] . Analytic sensitivity ranged from 99.4% -100%, with 1 laboratory reporting a single false-negative [17] . Given these data, there appears to be very little variability for the analytic specificity and sensitivity.
Clinical Validity : Test accuracy and reliability in predicting abacavir hypersensitivity (predictive value).
The prevalence of the HLA-B*5701 allele is highest in Caucasian populations (5-8%) [3] [18] [19] [20] . In African-American, Asian, and Hispanic populations, the prevalence is 0.26-3.6% [19] [20] [21] [22] . In a review of the adult and adolescent antiretroviral guidelines and the abacavir prescribing information [12] [16] , the prevalence of the HLA-B*5701 allele between ethnic populations has no impact on clinical recommendations.
In studies conducted in North America, Europe, and Australia where patients were diagnosed with an abacavir hypersensitivity reaction based on symptom presentation, HLA-B*5701 test sensitivity was 46-78% [22] [23] [24] . In contrast, HLA-B*5701 test sensitivity was 94-100% in patients with an immunologically confirmed (via skin patch testing) abacavir hypersensitivity reaction [25] [26] [27] . There is suggestion that the discrepancy of lower estimates of test sensitivity was the inclusion of non-abacavir related hypersensitivity reactions [28] .
HLA-B*5701 test specificity, regardless of whether the abacavir hypersensitivity reaction is based on symptom presentation or immunologic confirmation, is 90-100% [22] A report by Hughes et al. suggested a "high genetic penetrance of HLA-B*5701 in predisposing [patients] to abacavir hypersensitivity" [24] .
Clinical Utility : Net benefit of test in improving health outcomes
The PREDICT-1 study was a double-blind, prospective, randomized study of 1,956 patients from 19 countries. The incidence of confirmed abacavir hypersensitivity was 2.7% in the control group versus 0% in the HLA-B*5701 screened group (p<0.001) [25] . In another prospective study of 137 patients of an ethnically mixed French HIV population, the incidence of an abacavir hypersensitivity in the HLA-B*5701 screened group was 0% [29] .
The ARIES study was an open-label, multicenter, North American study of 725 patients. Patients who were HLA-B*5701 negative had less than 1% clinically suspected abacavir hypersensitivity, and none had positive skin patch tests at 30 weeks [30] .
HLA-B*5701 testing to prevent abacavir hypersensitivity has been reported to be cost-effective [24] [31] . In one study, HLA-B*5701 testing resulted in a cost-effectiveness ratio of $36,000 per quality-adjusted life expectancy compared to no testing [31] .
Educating/training of hospital staff, monitoring, and implementing facility services for HLA-B*5701 testing have been reported by several institutions [21] [32] [33] .
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